載入...
Riociguat for pulmonary arterial hypertension associated with congenital heart disease
OBJECTIVE: The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH). PATENT-2 was an open-label long-term extension to PATENT-1. Here, we explor...
Na minha lista:
| 發表在: | Heart |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMJ Publishing Group
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4680166/ https://ncbi.nlm.nih.gov/pubmed/26135803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/heartjnl-2015-307832 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|